WNT5A expression is regulated by the status of its promoter methylation in leukaemia and can inhibit leukemic cell malignant proliferation

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 367-376

  Deng, Gang ^a   Li, Zhao Quan ^a   Zhao, Chen ^a   Yuan, Yuan ^a   Niu, Chang Chun ^a   Pan, Jing ^a   Si, Wei Ke ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Complete remission cases; Leukaemia; Methylation; WNT5A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; WNT5A PROTEIN;

ADOLESCENT; ARTICLE; CD34 SELECTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; DEMETHYLATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION;

ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; CHILD; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; U937 CELLS; WNT PROTEINS; YOUNG ADULT;

EID: 78651352259     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1108     Document Type: Article

References (28)

1. Wodarz A and Nusse R: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59-88, 1998.
2. Miller JR: The Wnts. Genome Biol 3: Reviews3001, 2002.
3. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004. (Pubitemid 39488658)
4. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004.
5. Kestler HA and Kuhl M: From individual Wnt pathways towards a Wnt signalling network. Philos Trans R Soc Lond B Biol Sci 363: 1333-1347, 2008.
6. Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398, 2008. (Pubitemid 351589714)
7. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
8. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
9. Jones C and Chen P: Planar cell polarity signaling in vertebrates. Bioessays 29: 120-132, 2007. (Pubitemid 46340247)
10. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 16: 279-283, 2000.
11. Winkel A, Stricker S, Tylzanowski P, et al: Wnt-ligand-dependent interaction of TAK1 (TGF-beta-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling. Cell Signal 20: 2134-2144, 2008.
12. Ishitani T, Kishida S, Hyodo-Miura J, et al: The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23: 131-139, 2003. (Pubitemid 36008507)
13. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL and Moon RT: Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 133: 1123-1137, 1996.
14. Nomachi A, Nishita M, Inaba D, Enomoto M, Hamasaki M and Minami Y: Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J Biol Chem 283: 27973-27981, 2008.
15. Mikels AJ and Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. Plos Biol 4: e115, 2006.
16. Saitoh T, Mine T and Katoh M: Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9: 515-519, 2002.
17. Jonsson M, Dejmek J, Bendahl PO and Bendahl PO: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62: 409-416, 2002. (Pubitemid 34106413)
18. Huang CL, Liu D and Nakano J: Wnt-5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol 23: 8765-8773, 2005. (Pubitemid 46211522)
19. Ripka S, Konig A, Buchholz M, et al: WNT5A, target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28: 1178-1187, 2007. (Pubitemid 47062676)
20. O'Connell MP, French AD, Leotlela PD and Weeraratna AT: Assaying Wnt5A-mediated invasion in melanoma cells. Methods Mol Biol 468: 243-253, 2008.
21. Bui TD, Tortora G, Ciardiello F and Harris AL: Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A. Biochem Biophys Res Commun 239: 911-917, 1997. (Pubitemid 27504202)
22. Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T and Brabant G: Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005. (Pubitemid 40516581)
23. Liang H, Chen Q, Coles AH, et al: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4: 349-360, 2003. (Pubitemid 37491096)
24. Román-Gómez J, Jimenez-Velasco A, Cordeu L, et al: WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer 43: 2736-2746, 2007. (Pubitemid 350161849)
25. Ying J, Li H, Chen YW, Srivastava G, Gao Z and Tao Q: WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukaemia cell growth as a tumor suppressor. Blood 110: 4130-4132, 2007. (Pubitemid 350248475)
26. Martin V, Valencia A, Agirre X, et al: Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukaemia. Cancer Science 101: 425-432, 2010.
27. Román-Gómez J, Cordeu L, Agirre X, et al: Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukaemia. Blood 109: 3462-3469, 2007. (Pubitemid 46572536)
28. Liang HL, Coles AH, Zhu ZQ, et al: Non-canonical Wnt signaling promotes apoptosis in thymocyte development. J Exp Med 204: 3077-3084, 2007.